Nichols & Pratt Advisers LLP MA Raises Holdings in IQVIA Holdings Inc. $IQV

Nichols & Pratt Advisers LLP MA grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 3.0% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 135,620 shares of the medical research company’s stock after buying an additional 3,964 shares during the period. IQVIA accounts for approximately 1.6% of Nichols & Pratt Advisers LLP MA’s holdings, making the stock its 21st largest holding. Nichols & Pratt Advisers LLP MA’s holdings in IQVIA were worth $26,204,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of IQVIA by 3.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 356,505 shares of the medical research company’s stock worth $68,884,000 after acquiring an additional 10,317 shares during the last quarter. Wedbush Securities Inc. increased its stake in IQVIA by 13.7% during the second quarter. Wedbush Securities Inc. now owns 1,342 shares of the medical research company’s stock worth $259,000 after purchasing an additional 162 shares during the period. Thornburg Investment Management Inc. acquired a new position in shares of IQVIA in the second quarter valued at approximately $13,338,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in IQVIA by 9.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock valued at $315,772,000 after buying an additional 134,997 shares during the period. Finally, Royal London Asset Management Ltd. increased its position in shares of IQVIA by 1.0% during the second quarter. Royal London Asset Management Ltd. now owns 79,234 shares of the medical research company’s stock worth $15,310,000 after acquiring an additional 756 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQVIA stock opened at $260.48 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The business has a 50 day simple moving average of $222.14 and a 200-day simple moving average of $189.62. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $265.25. The stock has a market capitalization of $42.88 billion, a PE ratio of 32.32, a price-to-earnings-growth ratio of 2.24 and a beta of 1.18.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA’s revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the company posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has initiated a share buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. BMO Capital Markets upped their price objective on IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. William Blair upgraded IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. JPMorgan Chase & Co. boosted their target price on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a research note on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. This trade represents a 15.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 12,913 shares of company stock valued at $3,098,793. Corporate insiders own 1.70% of the company’s stock.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.